Abstract
Usually, malignant high blood pressure and severe renal damage are main characters in SSc. SRCs is a relatively rare condition, found in approximately 5% of all SSc patients. This study was carried out to summarize the contemporary evidence regarding the causes, risk factors, manifestations, management and prognosis of Sclerodermal Renal Crisis. a simple review was carried out, searching databases PubMed, Google Scholar, and EBSCO. The authors extracted the needed data and stated that SRCs continues to be a rare diagnosis affecting up to six percent of SSc patients, but has a high morbidity and death influence. SRCs presentation is varied, with hypertension, normal BP and renal insufficiency. Medics should be minded by potential SRCs presentations. Early detection and initiation of aggressive ACEi antihypertensive medication in ED could enhance patient outcomes and around 60% of SRCs patients need dialysis.
Highlights
Scleroderma, called systemic sclerosis (SSc), is a rare, lifestyles-threatening, autoimmune-mediated, substantial inflammatory connective tissue disease which comes as a complication of systemic sclerosis [1,2] causing fibrotic changes in the skin and vasculature, affecting major organ systems [3,4]
Most sclerotermal renal crisis (SRC) research have applied ad hoc criteria, which have significantly differed between investigations
Systemic sclerosis (SSc) is a systemic autoimmune disease (SSc) which is characterised by vasculopathy, inflammation and fibrosis in the skin and internal organs
Summary
Scleroderma, called systemic sclerosis (SSc), is a rare, lifestyles-threatening, autoimmune-mediated, substantial inflammatory connective tissue disease which comes as a complication of systemic sclerosis [1,2] causing fibrotic changes in the skin and vasculature, affecting major organ systems [3,4]. Apart from heterogeneity and rareness, the absence of a gold standards and criteria for classification are key hurdles for SRC research. Most SRC research have applied ad hoc criteria, which have significantly differed between investigations. In order to define categorization criteria for SRC, the Scleroderma Clinical Trials Consortium (SCTC) SRC Working group was established. The aim of this phase was to produce a core collection of elements in order to define SRC by means of a consensus technique. In order to create and validate SRC Classification Criteria, future investigations using data-driven methodologies will be required [16]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
